NASDAQ:DVAX - Dynavax Technologies Stock Price, Price Target & More

Get Started

$16.60 0.00 (0.00 %)

(As of 05/23/2018 02:54 AM ET)

Previous Close$16.60

Today's Range$16.45 - $16.80

52-Week Range$5.35 - $24.45

Volume1.10 million shs

Average Volume1.62 million shs

Market Capitalization$1.06 billion

P/E Ratio-9.60

Dividend YieldN/A

Beta0.86

About Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:DVAX

CUSIP26815810

Webwww.dynavax.com

Phone510-848-5100

Debt

Debt-to-Equity Ratio0.60

Current Ratio10.85

Quick Ratio10.83

Price-To-Earnings

Trailing P/E Ratio-9.60

Forward P/E Ratio-7.90

P/E GrowthN/A

Sales & Book Value

Annual Sales$330,000.00

Price / Sales3,132.37

Cash FlowN/A

Price / CashN/A

Book Value$3.29 per share

Price / Book5.05

Profitability

EPS (Most Recent Fiscal Year)($1.73)

Net Income$-95,150,000.00

Net Margins-31,635.17%

Return on Equity-60.61%

Return on Assets-48.71%

Miscellaneous

Employees170

Outstanding Shares62,270,000

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies (NASDAQ:DVAX) announced its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.14. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.82 million. Dynavax Technologies had a negative net margin of 31,635.17% and a negative return on equity of 60.61%. The firm's quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.60) earnings per share. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

5 Wall Street analysts have issued 1 year target prices for Dynavax Technologies' shares. Their predictions range from $25.00 to $30.00. On average, they anticipate Dynavax Technologies' stock price to reach $27.40 in the next twelve months. View Analyst Ratings for Dynavax Technologies.

What are Wall Street analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:

1. Cantor Fitzgerald analysts commented, "HEPLISAV-B Launched. Dynavax reported that HEPLISAV-B, a two-dose hepatitis B vaccine, has been launched in the U.S. with a 60-person field sales team covering 75% of the market. HEPLISAV-B was recommended by the CDC for use in the vaccination of adults, which the company believes is critical to drive broad insurance coverage and adoption. By now, 100% of Medicare lives, 74% of commercially-insured lives, and 60% of lives covered under Medicaid plans have HEPLISAV-B specific CPT codes, referencing the correct price. In the first two months following launch, the sales team met two-thirds of the targeted key accounts, corresponding to more than half of the addressable market. The sales cycle is estimated to be 6-8 weeks at this stage. As previously reported, the company has a drug supply of over 250,000 vials, with an additional 750,000 vials worth of raw material." (5/8/2018)
2. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (1/10/2018)
3. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)

Who are some of Dynavax Technologies' key competitors?

Some companies that are related to Dynavax Technologies include Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT) and The Medicines (MDCO).

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:

Mr. Eddie Gray, CEO & Director (Age 59)
Dr. Dennis A. Carson, Co-Founder & Director (Age 71)
Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 66)
Mr. David F. Novack, Sr. VP of Operations and Quality (Age 56)
Dr. Robert L. Coffman, Chief Scientific Officer and Sr. VP (Age 71)

Has Dynavax Technologies been receiving favorable news coverage?

Media stories about DVAX stock have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dynavax Technologies earned a news impact score of 0.12 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.69 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (8.13%), BlackRock Inc. (6.21%), Franklin Resources Inc. (4.32%), Federated Investors Inc. PA (3.89%), venBio Select Advisor LLC (2.65%) and Senvest Management LLC (2.46%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Robert Coffman and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.

Which major investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Millennium Management LLC, Federated Investors Inc. PA, C WorldWide Group Holding A S, Allianz Asset Management GmbH, Senvest Management LLC, Candriam Luxembourg S.C.A. and BlackRock Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include David F Novack, David Louis Johnson and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

Which major investors are buying Dynavax Technologies stock?

DVAX stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Franklin Resources Inc., Point72 Asset Management L.P., Chicago Capital LLC, DekaBank Deutsche Girozentrale, UBS Group AG, Fisher Asset Management LLC and Rock Springs Capital Management LP. View Insider Buying and Selling for Dynavax Technologies.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $16.60.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $1.06 billion and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]

MarketBeat Community Rating for Dynavax Technologies (DVAX)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		267 (Vote Outperform)
Underperform Votes:		250 (Vote Underperform)
Total Votes:		517

MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Dynavax Technologies (NASDAQ:DVAX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

5 Wall Street analysts have issued ratings and price targets for Dynavax Technologies in the last 12 months. Their average twelve-month price target is $27.40, suggesting that the stock has a possible upside of 65.06%. The high price target for DVAX is $30.00 and the low price target for DVAX is $25.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	2.80	2.80	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$27.40	$27.40	$27.60	$28.00
Price Target Upside:	65.06% upside	45.36% upside	58.62% upside	39.65% upside

Dynavax Technologies (NASDAQ:DVAX) Consensus Price Target History

Price Target History for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/16/2018	Cantor Fitzgerald	Set Price Target	Buy	$27.00	High
5/10/2018	JPMorgan Chase	Upgrade	Neutral ➝ Overweight	$25.00	High
3/9/2018	Royal Bank of Canada	Reiterated Rating	Buy	$25.00	Medium
2/21/2018	Cowen	Reiterated Rating	Buy	$30.00	Low
8/9/2017	William Blair	Reiterated Rating	Outperform	$30.00	High
9/2/2016	S&P Equity Research	Boost Price Target		$11.28 ➝ $16.01	N/A

(Data available from 5/23/2016 forward)

Dynavax Technologies (NASDAQ:DVAX) Earnings History and Estimates Chart

Earnings by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.15)
2019 EPS Consensus Estimate: ($1.22)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.47)	($0.47)	($0.47)
Q2 2018	1	($0.59)	($0.59)	($0.59)
Q3 2018	1	($0.57)	($0.57)	($0.57)
Q4 2018	1	($0.52)	($0.52)	($0.52)
Q1 2019	1	($0.44)	($0.44)	($0.44)
Q2 2019	1	($0.35)	($0.35)	($0.35)
Q3 2019	1	($0.26)	($0.26)	($0.26)
Q4 2019	1	($0.17)	($0.17)	($0.17)

Dynavax Technologies (NASDAQ DVAX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/31/2018		($0.61)					N/A
5/8/2018	Q1 2018	($0.49)	($0.63)	$0.82 million	$0.17 million	View	N/A
3/8/2018	Q4 2017	($0.11)	($0.43)	$0.53 million	$0.02 million	View	N/A
11/3/2017	Q3 2017	($0.53)	($0.38)	$0.28 million	$0.05 million	View	N/A
8/2/2017	Q2 2017	($0.50)	($0.41)	$0.15 million	$0.11 million	View	N/A
5/8/2017	Q1 2017	($0.60)	($0.60)	$0.75 million	$0.15 million	View	N/A
3/13/2017	Q4 2016	($0.85)	($0.56)	$2.90 million	$7.30 million	View	N/A
11/7/2016	Q3	($0.75)	($0.90)	$2.44 million	$0.20 million	View	N/A
8/5/2016	Q2	($0.68)	($0.75)	$1.58 million	$2.65 million	View	N/A
5/9/2016	Q1	($0.63)	($0.70)	$627.00 million	$942.00 million	View	N/A
3/8/2016	Q4	($0.75)	($0.70)	$1.15 million	$0.69 million	View	N/A
11/5/2015	Q3	($0.78)	($0.82)	$1.65 million	$1.20 million	View	N/A
8/7/2015	Q2	($1.00)	($0.80)	$3.05 million	$1.55 million	View	N/A
5/7/2015	Q1 2015	($0.95)	($0.97)	$1.26 million	$0.63 million	View	N/A
3/5/2015	Q4 2014	($1.06)	($0.85)	$2.15 million	$2.28 million	View	N/A
11/5/2014	Q314	($0.09)	($0.11)	$2.50 million	$2.21 million	View	N/A
8/7/2014	Q214	($0.06)	($0.09)	$2.26 million	$3.05 million	View	N/A
5/5/2014	Q1 2014	($0.06)	($0.05)	$4.22 million	$3.50 million	View	N/A
3/10/2014	Q413	($0.07)	($0.09)	$1.56 million	$2.80 million	View	N/A
11/7/2013	Q313	($0.10)	($0.09)	$1.83 million	$2.93 million	View	N/A
7/29/2013	Q2 2013	($0.10)	($0.09)	$2.91 million	$3.40 million	View	N/A
5/6/2013	Q113	($0.11)	($0.11)	$2.40 million	$2.10 million	View	N/A
3/1/2013	Q4 2012		($0.11)	$11.40 million	$1.80 million	View	N/A
11/1/2012	Q312	($0.08)	($0.10)	$5.00 million	$2.90 million	View	N/A
8/1/2012	Q2 2012	($1.00)	($0.90)			View	N/A
4/27/2012	Q1 2012	($0.80)	($1.06)			View	N/A
3/6/2012	Q4 2011	($0.70)	($0.30)			View	N/A
10/27/2011	Q3 2011	($1.30)	($1.23)			View	N/A
7/20/2011	Q2 2011	($1.10)	($0.90)			View	N/A
5/5/2011	Q1 2011	($1.50)	($1.58)			View	N/A
3/8/2011	Q4 2010	($1.40)	($1.43)			View	N/A
11/4/2010	Q3 2010	($0.30)	($0.55)			View	N/A
7/30/2010	Q2 2010	($1.30)	($3.41)			View	N/A
5/6/2010	Q1 2010		($1.69)			View	N/A
3/16/2010	Q4 2009		($7.31)			View	N/A
10/22/2009	Q3 2009	($2.40)	($2.37)			View	N/A
8/4/2009	Q2 2009	$0.40	$1.03			View	N/A
4/28/2009	Q1 2009	($0.20)	$1.28			View	N/A
3/2/2009	Q4 2008	($0.60)	$0.78			View	N/A
11/3/2008	Q3 2008	($1.10)	($1.36)			View	N/A
8/5/2008	Q2 2008	($2.40)	($1.53)			View	N/A
4/29/2008	Q1 2008	($2.30)	($3.12)			View	N/A
2/19/2008	Q4 2007	($3.40)	($3.04)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Dynavax Technologies (NASDAQ:DVAX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Dynavax Technologies (NASDAQ DVAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.47%
Institutional Ownership Percentage: 79.38%

Insider Trading History for Dynavax Technologies (NASDAQ:DVAX)

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ DVAX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2018	David F Novack	Insider	Sell	16,109	$16.30	$262,576.70
3/13/2018	David F Novack	Insider	Sell	34,214	$16.52	$565,215.28	21,613
3/9/2018	David F Novack	Insider	Sell	2,121	$17.97	$38,114.37	77,192
1/4/2018	David Louis Johnson	VP	Sell	3,092	$18.60	$57,511.20	7,780
12/13/2017	Robert Coffman	Insider	Sell	7,500	$18.90	$141,750.00
1/24/2017	Robert Janssen	VP	Buy	6,000	$4.04	$24,240.00	12,048
6/28/2016	Robert Janssen	VP	Buy	1,452	$13.68	$19,863.36	6,048
5/20/2016	Eddie Gray	CEO	Buy	2,750	$15.57	$42,817.50	5,050
5/12/2016	Robert Janssen	VP	Buy	1,000	$15.12	$15,120.00	1,000
8/14/2014	Eddie Gray	CEO	Buy	25,000	$1.49	$37,250.00
10/30/2013	Peggy V Phillips	Director	Buy	93,023	$1.08	$100,464.84
9/14/2012	Jennifer Lew	VP	Sell	18,750	$4.53	$84,937.50
9/13/2012	Robert Coffman	VP	Sell	8,000	$4.52	$36,160.00

(Data available from 1/1/2013 forward)

Dynavax Technologies (NASDAQ DVAX) News Headlines

Source:

Date	Headline
	Brokerages Anticipate Dynavax Technologies (DVAX) to Post -$0.59 Earnings Per Share www.americanbankingnews.com - May 22 at 7:20 PM
	The Market Completely Misunderstood The Dynavax SD-101 Data seekingalpha.com - May 22 at 8:55 AM
	4 Names to Watch Ahead of This Year's Key Cancer-Research Conference finance.yahoo.com - May 19 at 4:44 PM
	BidaskClub Upgrades Dynavax Technologies (DVAX) to "Hold" www.americanbankingnews.com - May 18 at 5:13 PM
	Dynavax (DVAX) to Present New Data for SD-101 in Combination with KEYTRUDA at ASCO www.streetinsider.com - May 18 at 10:27 AM
	Dynavax Technologies (DVAX) Cut to Hold at ValuEngine www.americanbankingnews.com - May 17 at 10:56 PM
	Should Dynavax Technologies Corporation’s (NASDAQ:DVAX) Recent Earnings Worry You? finance.yahoo.com - May 17 at 4:42 PM
	Cantor Fitzgerald Analysts Give Dynavax Technologies (DVAX) a $27.00 Price Target www.americanbankingnews.com - May 17 at 1:53 PM
	7 ‘Strong Buy’ Stocks Analysts Are Upgrading Now finance.yahoo.com - May 15 at 9:40 AM
	Dynavax Technologies (DVAX) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - May 11 at 8:29 PM
	BidaskClub Downgrades Dynavax Technologies (DVAX) to Sell www.americanbankingnews.com - May 11 at 8:05 PM
	Dynavax Will Not Be Another Synergy seekingalpha.com - May 11 at 10:11 AM
	Analysts Issue Forecasts for Dynavax Technologies' Q2 2018 Earnings (DVAX) www.americanbankingnews.com - May 11 at 9:05 AM
	JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference finance.yahoo.com - May 10 at 4:44 PM
	Dynavax Technologies (DVAX) Upgraded by JPMorgan Chase to Overweight www.americanbankingnews.com - May 10 at 4:23 PM
	Edited Transcript of DVAX earnings conference call or presentation 8-May-18 8:30pm GMT finance.yahoo.com - May 10 at 9:26 AM
	BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63 www.reuters.com - May 9 at 4:43 PM
	Dynavax Earnings: Excellent Progress On Vaccine Commercialization And Pipeline Development seekingalpha.com - May 9 at 9:13 AM
	Dynavax Technologies' (DVAX) CEO Eddie Gray on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 9:13 AM
	Dynavax Technologies (DVAX) Announces Earnings Results www.americanbankingnews.com - May 8 at 10:28 PM
	Dynavax Technologies (DVAX) Receives "Buy" Rating from Cantor Fitzgerald www.americanbankingnews.com - May 8 at 9:15 PM
	Dynavax Reports First Quarter 2018 Financial Results finance.yahoo.com - May 8 at 4:44 PM
	Dynavax Technologies Corporation (NASDAQ:DVAX) Is Expected To Breakeven finance.yahoo.com - May 7 at 9:47 AM
	Analysts Expect Dynavax Technologies (DVAX) Will Announce Quarterly Sales of $820,000.00 www.americanbankingnews.com - May 7 at 4:26 AM
	Dynavax Technologies (DVAX) Expected to Announce Earnings of -$0.51 Per Share www.americanbankingnews.com - May 5 at 9:32 AM
	Dynavax to Host First Quarter 2018 Financial Results Conference Call finance.yahoo.com - May 2 at 4:51 PM
	Dynavax Technologies (DVAX) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - May 2 at 1:42 AM
	Dynavax Technologies (DVAX) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - May 1 at 10:02 AM
	Dynavax Technologies (DVAX) Set to Announce Quarterly Earnings on Monday www.americanbankingnews.com - April 30 at 9:21 AM
	Dynavax’s HEPLISAV-B ACIP recommendations published in the CDC’s MMWR seekingalpha.com - April 23 at 9:29 AM
	Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report finance.yahoo.com - April 23 at 9:29 AM
	Dynavax Technologies (DVAX) Cut to "Hold" at BidaskClub www.americanbankingnews.com - April 22 at 6:46 AM
	$820,000.00 in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter www.americanbankingnews.com - April 20 at 4:25 AM
	Pre-Open Stock Movers 04/16: (ERI) (ALKS) (DVAX) Higher; (CLDX) (ALGT) (NLNK) Lower (more...) www.streetinsider.com - April 18 at 4:40 PM
	-$0.51 EPS Expected for Dynavax Technologies Co. (DVAX) This Quarter www.americanbankingnews.com - April 18 at 9:35 AM
	Dynavax: Positive Results, Market Confusion seekingalpha.com - April 18 at 9:27 AM
	Brokers Issue Forecasts for Dynavax Technologies Co.'s Q1 2019 Earnings (DVAX) www.americanbankingnews.com - April 18 at 8:42 AM
	Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting finance.yahoo.com - April 17 at 9:19 AM
	Dynavax Technologies (DVAX) Given a $27.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - April 16 at 6:30 PM
	Investors bullish on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma; shares up 14% premarket seekingalpha.com - April 16 at 9:34 AM
	Dynavax shares rise 14% on promising cancer conference data finance.yahoo.com - April 16 at 9:34 AM
	Dynavax Technologies (DVAX) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - April 16 at 7:00 AM
	Dynavax Technologies (DVAX) PT Set at $7.00 by Royal Bank of Canada www.americanbankingnews.com - April 15 at 5:39 PM
	Dynavax Technologies (DVAX) Upgraded to "Outperform" by Royal Bank of Canada www.americanbankingnews.com - April 15 at 9:45 AM
	Dynavax Technologies (DVAX) Rating Increased to Overweight at JPMorgan Chase www.americanbankingnews.com - April 15 at 9:43 AM
	Investors Buy High Volume of Put Options on Dynavax Technologies (DVAX) www.americanbankingnews.com - April 12 at 7:01 AM
	Dynavax Technologies' (DVAX) "Outperform" Rating Reaffirmed at Cowen www.americanbankingnews.com - April 11 at 5:01 PM
	Dynavax Technologies (DVAX) Rating Lowered to Hold at BidaskClub www.americanbankingnews.com - April 10 at 10:24 AM
	Dynavax Technologies Co. (DVAX) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 7 at 1:29 AM
	Watch These April Biotech Catalysts seekingalpha.com - April 3 at 9:10 AM

Dynavax Technologies (NASDAQ:DVAX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Dynavax Technologies (NASDAQ:DVAX) Income Statement, Balance Sheet and Cash Flow Statement

Dynavax Technologies (NASDAQ DVAX) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff